PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: A61K 38/18, A61P 9/10

A3

(11) International Publication Number:

WO 00/21548

٠,

(43) International Publication Date:

20 April 2000 (20.04.00)

(21) International Application Number:

PCT/US99/22936

(22) International Filing Date:

13 October 1999 (13.10.99)

(30) Priority Data:

60/104,103

13 October 1998 (13.10.98) US

(71) Applicants: CHIRON CORPORATION [US/US]; 4560 Horton Street, P.O. Box 8097, Intellectual Property R-440, Emeryville, CA 9662–8097 (US). WHITEHOUSE, Martha, Jo [-/US]; 151 Upper Terrace, San Francisco, CA 94117 (US).

- (72) Inventor: KAVANAUGH, William, M.; 205 Laverne Avenue, Mill Valley, CA 94941 (US).
- (74) Agents: DOLLARD, Anne; Chiron Corporation, 4560 Horton Street, P.O. Box 8097, Intellectual Property R-440, Emeryville, CA 94662-8097 (US) et al.

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

With international search report.

(88) Date of publication of the international search report:

31 August 2000 (31.08.00)

(54) Title: ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING



(57) Abstract

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μ g/kg to 36 μ g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μ g/kg to 36 μ g/kg of an FGF of any one of SEQ ID NOS: 1–3, 5, 8–10 or 12–14 or and angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS: 1–3, 5, 8–10 or 12–14, or an angiogenically active fragment or mutein thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
\mathbf{BF}	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	ΙE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	\mathbf{PL}	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Inter onal Application No PCT/US 99/22936

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/18 A61P9/10

According to international Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) $IPC\ 7\ A61K$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal WPI MEDLIN BIOSIS CA EMBASE LIFESC SCISEA

	IENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, o	Relevant to claim No.	
X	KIRSCHNER PAMELA B ET AL: "E fibroblast growth factor protexcitotoxicity and chemical hoth neonatal and adult rats. JOURNAL OF CEREBRAL BLOOD FLOMETABOLISM 1995, vol. 15, no. 4, 1995, pages 6 XP000906721 ISSN: 0271-678X the whole document	1,2, 13-20	
	About the state of		
<u> </u>	ther documents are listed in the continuation of box C.	Patent family members are	listed in annex.
Special c "A" docum consi "E" earlier filling "L" docum which citati "O" docum other "P" docum	ategories of cited documents : nent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	"T" later document published after the or priority date and not in conflicted to understand the principle invention. "X" document of particular relevance cannot be considered novel or convolve an inventive step when "Y" document of particular relevance cannot be considered to involve document is combined with one ments, such combination being in the art. "&" document member of the same p	e international filing date at with the application but be or theory underlying the annot be considered to the document is taken alone the taken alone the inventive step when the or more other such docu- obvious to a person skilled
"A" docum consi "E" earlier filing "L" docum which citati "O" docum other	ategories of cited documents: nent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but	"T" later document published after the or priority date and not in conflicted to understand the principle invention. "X" document of particular relevance cannot be considered novel or a involve an inventive step when: "Y" document of particular relevance cannot be considered to involve document is combined with one ments, such combination being in the art.	e international filing date at with the application but be or theory underlying the annot be considered to the document is taken alone at ithe claimed invention an inventive step when the or more other such docu— obvious to a person skilled
"A" docum consi "E" earlier filling "L" docum which citatis" "O" docum other "P" docum later	ategories of cited documents: nent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) nent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed	"T" later document published after the or priority date and not in conflicted to understand the principle invention. "X" document of particular relevance cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the cannot be considered to involve document is combined with one ments, such combination being in the art. "&" document member of the same p	e international filing date at with the application but be or theory underlying the annot be considered to the document is taken alone at ithe claimed invention an inventive step when the or more other such docu— obvious to a person skilled
A document consister of the country which citatis* *O* document of the country	ategories of cited documents: nent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) nent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed	"T" later document published after the or priority date and not in conflicated to understand the principle invention. "X" document of particular relevance cannot be considered novel or convolve an inventive step when a cannot be considered to involve document of particular relevance cannot be considered to involve document is combined with one ments, such combination being in the art. "&" document member of the same processes."	e international filing date at with the application but be or theory underlying the annot be considered to the document is taken alone at ithe claimed invention an inventive step when the or more other such docu— obvious to a person skilled

inter anal Application No
PCT/US 99/22936

0.40		PC1/US 99/22936
Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	oracion of document, with indication, whole appropriate, or the relevant passages	Helevanit to dain 140.
X	SELLKE FRANK W ET AL: "Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia." SURGERY (ST LOUIS) 1996, vol. 120, no. 2, 1996, pages 182-188, XP000891931 ISSN: 0039-6060 the whole document	1,2, 13-31
X	US 4 378 347 A (FRANCO W.P.) 29 March 1983 (1983-03-29) the whole document	1,2,13, 21
X	FOLKMAN J.: "Angiogenic therapy for the human heart" CIRCULATION, vol. 97, 1998, pages 628-629, XP000891914 the whole document	1,2, 11-31

1

. ... amational application No.

PCT/US 99/22936

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 21-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Inte	emational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

.nformation on patent family members

inte onal Application No PCT/US 99/22936

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 4378347	A	29-03-1983	US AU GB JP WO	4296100 A 7416981 A 2090528 A,B 57500878 T 8200098 A	20-10-1981 02-02-1982 14-07-1982 20-05-1982 21-01-1982